Content Type: Article

  • FDA 2020 Year in Review

    FDA 2020 Year in Review

    ARTICLE / REPORT

    FDA 2020 Year in Review

    January 2021

    Read time: 2 min

    Overview

    The US Food and Drug Administration (FDA) became a central focus of the nation and world’s attention in 2020, since the agency regulates many of the critically needed therapies, treatments, and interventions needed to mitigate and combat the COVID-19 pandemic. The agency faced many challenges in light of the inevitable politicization of a public health emergency, exercising rarely used authorities to facilitate an expedient response to the pandemic, in addition to pushing forward its traditional regulatory agenda.

    We review notable actions that shaped FDA-regulated industries and products in 2020 and offer insights into the agency’s 2021 expected actions and priorities in the following areas:

    • COVID-19 Response
    • Drugs and Biologics
    • Medical Devices
    • Digital Health
    • Laboratory-Developed Tests And Precision Medicine
    • Food
    • Dietary Supplements
    • Tobacco
    • Cannabis
    • Clinical Investigations
    • Advertising and Promotion
    • Enforcement
    In depth
    Tabs

    Michael W. Ryan

    Partner

    Washington, DC

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    More insights
    Endnotes

  • COVID-19 Vaccine FAQs for Employers

    ARTICLE

    COVID-19 Vaccine FAQs for Employers

    January 13, 2021

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • Google’s Fake Union Insults the Labor Movement

    ARTICLE

    Google’s Fake Union Insults the Labor Movement

    January 13, 2021

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • COVID-19 Stimulus Package Significantly Expands CARES Act Employee Retention Tax Credits

    COVID-19 Stimulus Package Significantly Expands CARES Act Employee Retention Tax Credits

    ARTICLE / CLIENT ALERT

    COVID-19 Stimulus Package Significantly Expands CARES Act Employee Retention Tax Credits

    January 12, 2021

    Read time: 8 min

    Key takeaways
    Overview

    The Consolidated Appropriations Act, 2021, which became law on December 27, 2020, makes significant changes to the employee retention tax credits available under the Coronavirus Aid, Relief and Economic Security Act (the CARES Act).

    The changes are generally designed to increase the availability, scope and amount of the credits. Significantly, certain employers that received a Payroll Protection Program (PPP) loan (or that were related to employers that received a PPP loan) may be eligible to claim the credit, including retroactively for periods beginning as early as March 13, 2020.

    For general information on the employee retention tax credits as originally included as part of the CARES Act, please see our client alert, “CARES Act Social Security tax deferral and employee retention credits.”

    In depth

    Now Available to Eligible Employers Who Received PPP Loans

    The PPP under the CARES Act allowed eligible employers to borrow up to $10 million at a fixed interest rate of 1% for a two-year term if the loan was used to pay certain business expenses, including payroll and employee benefits. PPP loans are forgivable if they are used to retain and pay employees, rent, utilities and interest on mortgage obligations during the eight-week period following loan origination. The Consolidated Appropriations Act authorized an additional $284 billion in PPP loans to be issued to eligible employers. For general information on the PPP, please see our client alert, “Small business relief in the CARES Act.”

    The CARES Act stipulated that an employer that received a loan under the PPP was ineligible to claim employee retention tax credits for any wages paid to its employees. The Consolidated Appropriations Act provides that an employer that received a PPP loan may claim the credit, including retroactively for periods beginning as early as March 13, 2020, as long as the employer does not claim the credit with respect to wages paid with the proceeds of a PPP loan that was forgiven. In other words, an employer may not receive a double benefit by claiming the credit on wages paid with loan proceeds that the Small Business Administration has forgiven. In contrast, however, an eligible employer may claim the credit for wages paid with PPP loan proceeds that are not forgiven.  In addition, eligible employers that pursue PPP loan forgiveness may still claim the credit for wages that are not covered by the forgiven PPP loan (i.e., wages that are not paid from such loan proceeds).

    This means that an employer that received a PPP loan in 2020 may still be eligible to capture the employer retention tax credit. Employers that claim the credit retroactively for wages paid in 2020 may generally claim the credit on their fourth-quarter Form 941 due by January 31, 2021. After that date, the methodology changes and requires more IRS interaction, including the employer’s proactive filing of refund claims and ensuing IRS review of those refund claim filings. Read our client alert, “Proposed JOBS Credit Act would significantly expand CARES Act employee retention tax credits,” for further details about claiming this credit for 2020. For details about retroactive eligibility of credits and relevant effective dates, please read our article, “COVID-19 stimulus package reverses course: PPP loan recipients are retroactively eligible for important payroll tax credits.”

    Additional Changes under the Consolidated Appropriations Act

    The Consolidated Appropriations Act made the following additional changes to the CARES Act employee retention credits, which are effective beginning on or after January 1, 2021:

    • Amount of the Credits. The credits available under the CARES Act equaled 50% of up to $10,000 in qualified wages that an eligible employer pays in a calendar quarter. The Consolidated Appropriations Act increased the amount of the credits to 70% of up to $10,000 in qualified wages that an eligible employer pays per calendar quarter, with a maximum credit of $7,000 per employee, per quarter. The maximum credit under the CARES Act for wages paid to any employee was $5,000. The Consolidated Appropriations Act increased the maximum credit for the first two quarters of 2021 to $14,000 per employee. The credit also is available even if an employer received the $5,000 maximum credit for wages paid to an employee in 2020. In addition, the Consolidated Appropriations Act removes the CARES Act cap on wages to allow the credit to be claimed on pay increases and bonuses in excess of the amount that the employee earned during the 30 days preceding the shutdown or the significant decline in gross receipts.
    • Large Employers. What constitutes qualified wages for which the employee retention credits can be claimed depends on the size of the employer’s average full-time workforce in 2019, with more stringent criteria for larger businesses. The Consolidated Appropriations Act increased the threshold for determining a large employer from 100 employees under the CARES Act to employers with more than 500 full-time employees in 2019. This change would allow more employers to be considered small employers and claim the credits on all wages paid to employees, even if the employees are providing services during the period for which the credits are claimed. In contrast, an employer with more than 500 full-time employees in 2019 may claim the credit only for wages paid to an employee while the employee is not performing services for the employer.
    • Gross Receipts Test. An employer’s initial eligibility for the credits is triggered if either of two COVID-19 economic hardships arise within a calendar quarter for 2020. The second of these economic hardships is a significant decline in gross receipts, which occurs during a calendar quarter when the employer’s gross receipts are less than 50% of the employer’s gross receipts for the same calendar quarter in 2019. The Consolidated Appropriations Act now only requires a 20% (rather than 50%) reduction in gross receipts to qualify for the credit, thereby making it easier for employers to be an eligible employer for this credit. . Employers that experience a full or partial suspension of business operations due to a COVID-19-related governmental order will also continue to qualify for the credit, regardless of the amount of an employer’s total gross receipts.
    • Government Employers’ Eligibility. Under the CARES Act, credits were not available to federal, state and local governments and their political subdivisions, agencies and instrumentalities. However, the Consolidated Appropriations Act eliminates this limitation for certain governmental entities beginning in 2021. As a result, certain public entities may now qualify for the credit. This includes colleges and universities, entities with the principal purpose or function of providing medical or hospital care and certain tax-exempt corporations organized as an instrumentality of the United States.

    Comparing the CARES Act and the Consolidated Appropriations Act

     

    CARES Act Consolidated Appropriations Act
    Amount of Credits The credits equal 50% of up to $10,000 in qualified wages that an eligible employer pays in a calendar quarter for periods from March 13, 2020, to December 31, 2020. The maximum credit is $5,000.

    The wages for which an employer could claim the credit were capped at the amount the employee would have received for working an equivalent duration during the 30 days preceding the shutdown or the significant decline in gross receipts.

    Effective January 1, 2021, to June 30, 2021, the credits equal 70% of up to $10,000 in qualified wages that an eligible employer pays per calendar quarter, with a maximum credit of $7,000 per employee, per quarter. The maximum credit for the first two quarters of 2021 is therefore increased to $14,000 per employee. The credit also is available even if an employer received the $5,000 maximum credit for wages paid to an employee in 2020.

    In addition, the CARES Act cap on wages is removed, which allows the credit to be claimed on pay increases and bonuses paid in excess of what the employee earned prior to the shutdown or significant declined in gross receipts.

    Large Employers A large employer for purposes of determining qualified wages is an employer who averaged more than 100 full-time employees in 2019. Effective January 1, 2021, a large employer for purposes of determining qualified wages is an employer who averaged more than 500 full-time employees in 2019.
    Gross Receipts Test An employer is eligible for the credits if the employer’s gross receipts are less than 50% of gross receipts for the same calendar quarter in 2019. Effective January 1, 2021, an employer is eligible for the credits if the employer’s gross receipts are less than 80% of gross receipts for the same calendar quarter in 2019.
    Governmental Employers’ Eligibility The employee retention credit was not available to any federal, state or local governments, or any agency or instrumentality thereof. Effective January 1, 2021, the employee retention credit is available to public colleges or universities, organizations whose principal purpose is providing medical or hospital care and certain federal instrumentalities.

     

    Authors

    Andrew C. Liazos

    Partner

    Boston, New York – One Vanderbilt Avenue

    Brian J. Tiemann

    Partner

    Chicago

    More insights

  • Innovative Finance Focus: Doing More With Less Through Recoverable Grants

    ARTICLE

    Innovative Finance Focus: Doing More With Less Through Recoverable Grants

    January 12, 2021

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors

    Carl J. Fleming

    Partner

    Washington, DC

    More insights

  • Consolidated Appropriations Act: Health and Welfare Benefits Provisions

    Consolidated Appropriations Act: Health and Welfare Benefits Provisions

    ARTICLE / CLIENT ALERT

    Consolidated Appropriations Act: Health and Welfare Benefits Provisions

    January 12, 2021

    Read time: 8 min

    Key takeaways
    Overview

    The Consolidated Appropriations Act (the “Act’”) was signed into law by the president on December 27, 2020, and includes significant health and welfare benefits provisions that affect group health plans and health insurance issuers. The Act is the most comprehensive single piece of legislation to impact group health plans since the Affordable Care Act (ACA).

    This On the Subject summarizes the key provisions of the Act that apply to group health and welfare plan sponsors. The Act includes provisions regarding (1) flexible spending arrangements; (2) surprise medical billing; (3) mental health and substance use disorder benefits; (4) pharmacy benefits reporting; and (5) disclosure of service provider compensation. (For more information, read the article “Summary of key health provisions in the Consolidated Appropriations Act, 2021.”)

    In depth

    Flexible Spending Arrangements (FSAs)

    FSA plan sponsors are allowed, but not required, to amend their cafeteria plans to take advantage of the new relief provisions described below by the end of the first calendar year beginning after the end of the plan year in which the change takes effect. (For example, if mid-year election changes are allowed in 2021, a calendar year plan must be amended by December 31, 2022.) In addition, the plan must be operated in accordance with the amendment terms as of the effective date of the amendment.

    • Mid-Year Election Changes

    For plan years ending in 2021, a plan may allow participants to change the number of their contributions to healthcare or dependent care FSAs prospectively, without regard to any change in status.

    • Carryover of Account Balances

    A plan may allow participants to carry over any unused amounts or contributions remaining in a healthcare or dependent care FSA from the 2020 plan year to the 2021 plan year, or the 2021 plan year to the 2022 plan year.

    • Grace Period Extension

    Both healthcare and dependent care FSAs may extend their grace period to 12 months after the end of the plan year, for plan years ending in 2020 or 2021.

    • Unused Healthcare FSA Account Balances

    A plan may allow an employee who terminates their participation in a healthcare FSA during the 2020 or 2021 calendar year to continue to receive reimbursements from unused account balances through the end of the plan year in which such participation ended (including any applicable grace period).

    • Dependent Care FSA & Aging Out

    For dependents who aged out of eligibility during the pandemic (specifically, during the last plan year with a regular enrollment period ending on or before January 31, 2020), plans may extend the maximum age from 13 to 14.

    Surprise Medical Billing Provisions

    For plan years beginning on or after January 1, 2022, employer-sponsored medical plans that cover emergency services must offer services without requiring preauthorization determinations, regardless of whether a health provider that delivers the services is a participating provider in the plan’s network or the emergency facility. Such non-ancillary services now must be furnished without coverage limits or requirements that are more stringent than those for emergency services delivered by participating providers. In addition, any cost-sharing requirements for out-of-network services may not be greater than those for services provided by in-network providers. The Act also prohibits air ambulance services from balance billing individuals covered by a group health plan or individual or group health insurance.

    • Out-of-Network Rate Determinations: Independent Dispute Resolution Process

    Like many state surprise billing laws, the Act includes open negotiation and independent dispute resolution (IDR) procedures for use by plans or insurers and non-participating providers to determine the amount that will be paid for a provided service. The parties can participate in a 30-day open negotiation process that begins on the day the provider receives the plan’s initial payment (or denial notice) regarding the service.

    If the plan or insurer and provider cannot agree to a payment amount during the 30-day open negotiation period, either party may then invoke the IDR process by providing notice to the other party and the Department of Health and Human Services (HHS). If this occurs, a “certified IDR entity” will determine the payment amount for the service. Under implementing guidance concerning the IDR process (to be issued in the future), there will be criteria for jointly determining the payment amounts as to multiple disputed items (for example, if services are related to treatment for a similar condition). More detail is expected in the form of agency guidance.

    • Health Plan Advance Estimates

    Beginning in 2022, if a participant schedules a healthcare service to be performed by a provider with sufficient advance notice, the provider must provide advance notice to the health plan. Group health plans and insurers that receive the provider’s notice regarding a participant’s scheduled service must furnish the participant a notice—in most cases, within one business day of receiving the provider’s notice—that contains specified coverage information.

    For example, the plan’s notice to a participant must state whether the provider is a participating provider as to the scheduled service and, if so, the contracted rate for the service based on relevant billing and diagnostic codes. The notice must also include a good faith estimate of how much the health plan will pay for the scheduled services.

    • External Review and Surprise Medical Billing

    On or before January 1, 2022, health plans must apply the external review procedures of the ACA to benefit denials relating to the Act’s surprise medical billing provisions.

    Mental Health and Substance Use Disorder Benefits

    Plan sponsors that provide both medical/surgical benefits and mental health or substance use disorder benefits and that impose non-quantitative treatment limitations (NQTLs) on mental health or substance use disorder benefits are required to perform and document comparative analyses of the design and application of NQTLs. Beginning February 10, 2021, these analyses must be made available to the Department of Labor (DOL), HHS or Internal Revenue Service (IRS) upon request. Employers whose plans impose separate limitations on mental health benefits (e.g., precertification) will need to test the program and keep a copy of the current test in the event one of the agencies requests it.

    Pharmacy Benefits Reporting

    By December 27, 2021, and annually thereafter, plans will be required to submit to the DOL, HHS and IRS a report with specific information on the benefits paid for prescription drugs provided to participants and beneficiaries. As a result, plan sponsors must immediately begin recording:

    The dates of the plan year, number of participants and beneficiaries, and each state in which coverage is offered;

    • The 50 brand prescription drugs most frequently dispensed and the total number of paid claims for each drug;
    • The 50 most costly prescription drugs by total annual spending;
    • The 50 prescription drugs with the greatest increase in plan expenditures over the preceding plan year;
    • Average monthly premium paid by the employer and by participants and beneficiaries; and
    • Impact of rebates, fees and other remuneration paid by drug manufacturers on premiums and out-of-pocket costs.

    Disclosure of Service Provider Compensation

    Service providers for welfare plans were temporarily exempt from the Employee Retirement Income Security Act (ERISA) requirement to provide fee disclosures to plan fiduciaries; however, the Act ends that reprieve and extends the fee disclosure rules to group health plans. Service providers for group health plans must comply with fee disclosure rules effective December 27, 2021. Such fee disclosure potentially applies to any group health plan vendors—including brokers and consultants—that provide services to a group health plan funded with plan assets.

    Practical Application

    Plan sponsors will need to take action to comply with the Act. Most immediately, plan sponsors should determine whether to incorporate the elective FSA relief provisions of the Act for the 2021 plan year and communicate any such changes to participants as soon as possible. In addition, plan sponsors should begin collecting appropriate data to ensure compliance with required reporting under the Act that must occur before the end of 2021. In addition, plan sponsors should update plan documents and summary plan descriptions for a number of the Act’s provisions, as well as related forthcoming guidance. Finally, plan sponsors should review their vendor agreements, such as administrative services agreements and pharmacy benefit manager agreements, to ensure that any data collection and reporting provisions are consistent with the requirements of the Act.

    We anticipate that most employer-sponsored group health plans will attempt to meet the Act’s disclosure obligations (some of which appear to overlap with the obligations of the recently issued price transparency regulations) by using third-party providers on behalf of the plan. Plan sponsors should exercise caution when contracting with third-party providers to fulfill their obligations under the Act, to ensure both that they are able to meet the heavy burdens of the Act and that the plan and company are sufficiently indemnified and protected should the provider fall short. For more information on how your group health plan should comply with these changes, please contact your regular McDermott employee benefits lawyer or one of the authors.

    Authors

    Jacob M. Mattinson

    Partner

    Chicago

    Sarah G. Raaii

    Partner

    Chicago

    More insights

  • NYSE Proposes to Permanently Amend ‘Related Party’ and ‘20%’ Stockholder Approval Rules

    NYSE Proposes to Permanently Amend ‘Related Party’ and ‘20%’ Stockholder Approval Rules

    ARTICLE / CLIENT ALERT

    NYSE Proposes to Permanently Amend ‘Related Party’ and ‘20%’ Stockholder Approval Rules

    January 12, 2021

    Read time: 4 min

    Key takeaways
    Overview

    In April 2020, the NYSE initially adopted, and the SEC approved, a temporary waiver (“NYSE Waiver”) of certain NYSE stockholder approval rules set forth in Section 312.03 of the NYSE Listed Company Manual (“NYSE Manual”) in order to lessen the hurdles companies face when seeking to raise capital, as many needed to do during the COVID-19 pandemic.[1]

    After a series of extensions of the NYSE Waiver (the latest through March 31, 2021), the NYSE is proposing to officially amend Section 312.03 of the NYSE Manual. The proposed rule change will now go through a notice and comment period, but, if adopted, will make permanent the following.

    Rule 312.03(b) — The Related Party Stockholder Approval Rule, as amended, would:

    • No longer require prior stockholder approval for issuances to the subsidiaries, affiliates or other closely related persons of directors, officers and substantial security holders (“Related Party”) or to entities in which a Related Party has a substantial interest (except where a Related Party has a 5% or greater interest in the counterparty (as described below)).
    • No longer require stockholder approval of issuances in a cash sale that meets the NYSE minimum price requirement to a Related Party. This would be the case even where the number of shares of common stock to be issued (or the number of shares of common stock into which the securities may be convertible or exercisable) exceeds either 5% of the number of shares of common stock or of the voting power outstanding before the issuance.
    • Require stockholder approval of any transaction or series of related transactions in which any Related Party has a 5% or greater interest (or collectively have a 10% or greater interest), directly or indirectly, in the company or assets to be acquired or in the consideration to be paid in the transaction and the issuance of common stock, or securities convertible into common stock, could increase the outstanding common shares by 5% or more.
    • Delete now irrelevant provisions relating to: (i) cash sales that meet the NYSE minimum price requirement, and where the issuance does not exceed 5% of the shares of common stock or voting power before the issuance, to a Related Party where the Related Party involved in the transaction is classified as such solely because such person is a substantial security holder; and (ii) an exemption related to early-stage companies.

    Rule 312.03(c) — The 20% Stockholder Approval Rule, as amended, would:

    • Replace the reference to “bona fide private financing” in the exception from shareholder approval for transactions relating to 20% or more of the company’s outstanding common stock or voting power with “other financing (that is not a public offering for cash) in which the company is selling securities for cash.” This would eliminate the 5% limit for any single purchaser participating in such a transaction, thus permitting companies to consummate a financing to a single purchaser.
    • Require shareholder approval if any of the proceeds of such a financing will be paid in an acquisition and the securities generating such proceeds when combined with any securities issued in connection with such acquisition exceed either 20% of the number of shares of common stock or of the voting power outstanding before the issuance.

    In addition, Section 314 of the NYSE Manual would be amended to require a company’s audit committee or other independent body of the board of directors to review related party transactions, which for purposes of Section 314 would mean those transactions required to be disclosed pursuant to Item 404 of Regulation S-K under the Securities Exchange Act of 1934, as amended.

    Authored by Ele Klein and Evan A. Berger.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] See “NYSE Further Extends Waiver of Parts of ‘Related Party’ and ‘20%’ Stockholder Approval Rules,” SRZ Alert, Oct. 9, 2020.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2021 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Ele Klein

    Partner

    New York – 919 Third Avenue

    More insights

  • HHS Advisory Opinion Concludes Manufacturers Must Deliver 340B Drugs to Contract Pharmacies

    HHS Advisory Opinion Concludes Manufacturers Must Deliver 340B Drugs to Contract Pharmacies

    ARTICLE / CLIENT ALERT

    HHS Advisory Opinion Concludes Manufacturers Must Deliver 340B Drugs to Contract Pharmacies

    January 11, 2021

    Read time: 8 min

    Key takeaways
    Overview

    On December 30, 2020, the US Department of Health and Human Services (HHS) Office of General Counsel (OGC) released an Advisory Opinion concluding that providers participating in the 340B Program (“covered entities”) are entitled to purchase covered outpatient drugs at 340B discounted prices even when those drugs are distributed by third-party contracted pharmacies (“contract pharmacies”) on the covered entity’s behalf. The Advisory Opinion responds to drug manufacturers who have recently declined to distribute 340B drugs through contract pharmacies. The Advisory Opinion is available here.

    In depth

    Background

    Guidance issued by the Health Resources and Services Administration (HRSA) in 1996 provided that 340B covered entities may elect to sign a contract with a pharmacy to dispense drugs purchased at 340B prices to the covered entity’s patients. The 1996 guidance generally limited the contract pharmacy option to those covered entities without an in-house pharmacy and to one pharmacy per covered entity. In 2010, HRSA released new guidance expanding contract pharmacy arrangements to all covered entities and removing the limit on the number of pharmacies with which a covered entity could contract.

    Recently, certain drug manufacturers have established restrictions or prohibitions on the sale of 340B drugs for dispensing through contract pharmacy arrangements. These programs have been based, in part, on claims by manufacturers that: (1) the use of contract pharmacies is not contemplated by the 340B Statute, (2) the guidance issued by HRSA in 1996 and 2010 were not issued in accordance with legal requirements pursuant to the Administrative Procedures Act because they represented substantive changes in the rights and obligations of the affected parties without promulgation through regulation, and (3) the use of contract pharmacies has led to duplicate discounts and diversion of drugs to ineligible patients. Covered entities have generally taken the position that these actions by drug manufacturers violate the 340B Statute, which requires that drug manufacturers offer covered entities covered outpatient drugs at 340B prices but does not expressly refer to the use of contract pharmacies.

    The Advisory Opinion

    The Advisory Opinion sets forth OGC’s analysis of the 340B Statute and addresses both its plain meaning and the statute’s purpose and history. With respect to the 340B Statute’s plain meaning, OGC emphasized that the “core requirement” of the 340B Statute is that manufacturers offer covered outpatient drugs at or below the ceiling price for drugs “purchased by” covered entities. With respect to the meaning of “purchased by,” OGC reasoned that the contract pharmacy model, whereby drugs are sold by the manufacturer to the covered entity and the covered entity takes title and pays the manufacturer, constitutes the “purchase” of the drug, regardless of where the drug is ultimately delivered (e.g., to a contract pharmacy).

    OGC further acknowledged that contract pharmacies have been an integral part of the 340B Program since its outset. OGC also reasoned that HRSA’s consistent position over the prior decades relating to contract pharmacies was not legislative rulemaking, but rather guidance intended to explain the statutory language by clarifying its meaning—it did not create new law, rights or duties that were not otherwise present in the statute. The Advisory Opinion does not, however, include the level of consideration of Administrative Procedures Act requirements that would be conducted under judicial review by a federal court.

    OGC rejected the rationale that manufacturers may restrict distributing 340B drugs to contract pharmacies because such arrangements lead to a heightened risk of diversion and duplicate discounts. In the Advisory Opinion, OGC noted that manufacturers have not identified any language in the 340B Statute that would support such a position. However, OGC recognized that the 340B Statute provides specific actions manufacturers may take in cases of suspected duplicate discounts or diversion (i.e., conducting an audit and submitting a claim for administrative dispute resolution), but the 340B Statute does not allow manufacturers to cut off contract pharmacies as a preventative measure.

    Finally, OGC opined that the legitimate transfer of drugs to contract pharmacies to dispense to patients of the covered entity does not constitute diversion of 340B drugs. OGC reasoned that diversion means that “on net, covered outpatient drugs end up in the hands of persons who are not patients of the covered entity.” It then recognized that if transferring 340B drugs to an agent of the covered entity, such as a contract pharmacy, was considered diversion, covered entities would be prohibited from handing off 340B drugs to anyone other than an employee or patient—even shipping 340B drugs to patients by common couriers would be prohibited. Ultimately, OGC concluded that the prohibition on a covered entity “otherwise transfer[ring]” a 340B drug must be interpreted in the context of a “resale” of the drug.

    Under the position taken by OGC in the Advisory Opinion, manufacturers are required by statute to sell covered outpatient drugs to covered entities at no more than the 340B ceiling price—regardless of the location where the drugs are delivered or the drug dispensing arrangement.

    Key Takeaways

    Potential Impact on Contract Pharmacy Distribution Models

    The Advisory Opinion sets forth the current legal view of the HHS OGC—it is not a law or regulation. It represents the HHS OGC’s legal interpretation of the law as of the day it was published. As a general matter, HHS OGC advisory opinions do not create new legal rights or obligations; rather, they clarify HHS OGC’s interpretation of existing legal rights or obligations.

    In this case, the Advisory Opinion clarifies HHS’s interpretation that the 340B Statute requires manufacturers to offer covered outpatient drugs at no more than the 340B price even if the purchased drugs are distributed through a contract pharmacy. While it follows from the Advisory Opinion that the HHS OGC would consider manufacturers charging covered entities above the 340B price for drugs distributed through contract pharmacies to be overcharging covered entities in violation of the 340B Statute, the issuance of the Advisory Opinion does not result in imposition of penalties on manufacturers or require that they resume sales to covered entities at 340B prices. The Advisory Opinion could portend HRSA manufacturer audits or other enforcement actions against manufacturers for noncompliance with the 340B Statute. The Advisory Opinion may also form the foundation for covered entities to challenge purchasing restrictions in the new Administrative Dispute Resolution (ADR) process set to take effect next month. For additional analysis of the ADR process, please see our previous On The Subject, linked here.

    Ultimately, it will likely be necessary for a federal court to determine the merits of the arguments and conclusions set forth in the Advisory Opinion. On December 11, 2020, a group of hospital plaintiffs filed a lawsuit against HHS alleging HRSA arbitrarily and capriciously failed to require manufacturers to ship 340B drugs to contract pharmacies or refer the matter to the HHS Office of Inspector General, in violation of the Administrative Procedure Act.

    Relevance to Manufacturer Data Collection and Auditing Activities

    The Advisory Opinion concludes that manufacturers are required to offer 340B drugs to covered entities that use contract pharmacies to aid in distributing 340B drugs, but its conclusion does not expressly address recent data sharing requirements imposed by certain manufacturers for covered entities to register contract pharmacies as distribution locations. However, the Advisory Opinion reaches its conclusion by reasoning that “neither [HRSA] nor a private actor is authorized by section 340B to add requirements to the statute,” and “if a covered entity using contract pharmacy services requests to purchase a covered drug from a participating manufacturer, the statute directs the manufacturer to sell the drug at the discounted price” (quoting and validating HRSA guidance). The Advisory Opinion further provides that manufacturers concerned about covered entity compliance must: (1) conduct an audit and (2) submit the claim to the ADR process. It continues that a covered entity’s failure to comply with the audit requirement still does not relieve manufacturers from the obligation to conform to the pricing requirements as provided in the 340B Statute.

    A Change of Administration

    It is likely that the upcoming administration of President-elect Joseph R. Biden would act in accordance with the conclusions of the Advisory Opinion. On December 14, 2020, California Attorney General Xavier Becerra along with attorneys general of 27 states and the District of Columbia issued a letter to HHS calling on Secretary Alex Azar to address the violations of the 340B Statute related to the statutory responsibilities of drug manufacturers in providing covered outpatient drugs at 340B ceiling prices for drugs dispensed at contract pharmacies. Notably, Attorney General Becerra is Mr. Biden’s nominee for Secretary of HHS.

    Authors

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    James A. Cannatti III

    Partner

    Washington, DC

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    Steven J. Schnelle

    Partner

    New York – One Vanderbilt Avenue

    Cathy Ren

    Partner

    Los Angeles

    More insights

  • The Strengths of the Private Debt Market Will Enable it to Rebound from this Recession

    ARTICLE

    The Strengths of the Private Debt Market Will Enable it to Rebound from this Recession

    January 11, 2021

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors

    Aymen Mahmoud

    Partner

    London – 22 Bishopsgate

    More insights

  • SolarWinds – Einstein Failed Us, and the Cyber Insurance Markets will Feel the Squeeze

    ARTICLE

    SolarWinds – Einstein Failed Us, and the Cyber Insurance Markets will Feel the Squeeze

    January 11, 2021

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights